Sage Therapeutics, Inc. (NASDAQ:SAGE) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET
Company Participants
Helen Rubinstein - IR
Barry Greene - CEO
Albert Robichaud - Chief Scientific Officer
Chris Benecchi - Chief Business Officer
Kimi Iguchi - CFO
Conference Call Participants
Ritu Baral - Cowen
Paul Matteis - Stifel
Ami Fadia - Needham
Jay Olson - Oppenheimer
Swapnil Malekar - Piper Sandler
Yatin Suneja - Guggenheim
Marc Goodman - SVB Leerink
Gospel Enyindah-Asonye - Morgan Stanley
Gary Nachman - BMO
Neena Bitritto-Garg - Citi
Stephen Mallon - RBC Capital Markets
Alex Nackenoff - Raymond James
Operator
Good morning. Welcome to Sage Therapeutics' Second Quarter 2022 Financial Results Conference Call. Currently, all participants are in listen-only mode. This call is being webcast live on the Investors and Media section of Sage’s website at sagerx.com. This call is the property of Sage Therapeutics and recording, reproduction, or transmission of this call without the expressed written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.
I would now like to introduce Helen Rubinstein, Director of Investor Relations at Sage.
Helen Rubinstein
Good morning, and thank you for joining Sage Therapeutics' second quarter 2022 financial results conference call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at sagerx.com where you can find the press release related to today's call as well as the slides that contain supplemental detail.
I'd like to point out that we will be making forward-looking statements which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. Please consult the risk factors discussed in today's press release and in our SEC filings for additional detail.
We will begin the call with prepared remarks by Barry Greene, our Chief Executive Officer, who will provide an overview of our progress during the second quarter. We will also be joined by Al Robichaud, our Chief Scientific Officer, who will review recent progress and development activities across our program; Chris Benecchi, our Chief Business Officer, who will provide an update on our progress preparing for the launch of the zuranolone in MDD and PPD, if approved; and Kimi Iguchi, our Chief Financial Officer, who will review the financial results from the quarter.
With that, I'll now turn the call over to Barry.